BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

About this update from Biomark Diagnostics, Inc.

[{"type":"text","content":"Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.","length":155,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer.","length":438,"tagName":"p"},{"type":"text","content":"The newly granted Chinese patent (N° ZL 201980092723.X) and Japanese patent (N° 2023-111262) cover BioMark's technology for detecting lung cancer by measuring specific metabolite biomarkers. In a recent study published in the International Journal of Molecular Sciences, BioMark's patented platform has shown a market-leading sensitivity of over 90% for early-stage lung cancer. This capability empowers clinicians to deliver fast, actionable results that can significantly improve patient outcomes.","length":507,"tagName":"p"},{"type":"text","content":""Securing these patents in two of Asia's largest healthcare markets is a transformational milestone for BioMark," said Rashid Ahmed Bux, President & CEO of BioMark. "Our technology is directly aligned with the next wave of liquid biopsy adoption across the region. These patents not only strengthen our global IP estate but also position us to capture significant commercial and clinical leadership, opening up new opportunities for expansion, technology licensing, and strategic partnerships."","length":522,"tagName":"p"},{"type":"text","content":"Granting of these strategic intellectual properties comes as Asia's major markets, China and Japan, face high and rising lung cancer rates. The liquid biopsy market in China is forecast to surpass US$670 million by 2030, while Japan is projected to reach over US$912 million by the same year, both with robust double-digit growth. National screening policies and an expanding commitment to advanced diagnostics are driving this rapid adoption.","length":447,"tagName":"p...

More updates from Biomark Diagnostics, Inc.